Literature DB >> 27530831

CTX-M-15 in combination with aac(6')-Ib-cr is the most prevalent mechanism of resistance both in Escherichia coli and Klebsiella pneumoniae, including K. pneumoniae ST258, in an ICU in Uruguay.

Inés Bado1, Claudia Gutiérrez2, Virginia García-Fulgueiras1, Nicolás F Cordeiro1, Lucía Araújo Pirez1, Verónica Seija2, Cristina Bazet2, Gloria Rieppi3, Rafael Vignoli4.   

Abstract

The objectives of this study were (i) to determine the extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae (ESBL-EcKp) clones circulating in an intensive care unit (ICU) in Uruguay between August 2010 and July 2011, (ii) to characterise the ESBL and plasmid-mediated quinolone resistance (PMQR) genes of the studied isolates and (iii) to determine the virulotype of the clinical isolates. Clinical and gut-colonising ESBL-EcKp from ICU patients were studied. Bacterial identification and antibiotic susceptibility determination were performed using a VITEK(®)2 system. Detection of ESBL, KPC and PMQR genes was performed by PCR and sequencing. Clonality was assessed by pulsed-field gel electrophoresis (PFGE) and multilocus sequence typing (MLST). In total, 54 ESBL-EcKp isolates (40 K. pneumoniae and 14 E. coli), with or without PMQR genes, were recovered from 30 of 68 inpatients. Forty-seven isolates were CTX-M-15-producers (36 as a single ESBL and 11 together with CTX-M-14). In addition, four isolates produced CTX-M-14, two produced CTX-M-2 and one produced SHV-5. No carbapenemases were detected either in E. coli or K. pneumoniae isolates. Among the ESBL-producing isolates, 42 also harboured PMQR genes: 27 aac(6')-Ib-cr; 14 aac(6')-Ib-cr and qnrB; and a single isolate carrying only qnrB. K. pneumoniae ST258, ST48 and ST16 and E. coli ST10 and ST405 were detected in 46/54 isolates, including 9 clinical isolates. In conclusion, non-KPC-producing K. pneumoniae ST258 harbouring different ESBL and PMQR genes was the main clone disseminated in the ICU. Extensive surveillance measures must be implemented to prevent the emergence of acquired plasmid-encoded blaKPC by ST258 K. pneumoniae.
Copyright © 2016 International Society for Chemotherapy of Infection and Cancer. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  ESBL; Extended-spectrum β-lactamase; Klebsiella pneumoniae; ST258

Mesh:

Substances:

Year:  2016        PMID: 27530831     DOI: 10.1016/j.jgar.2016.02.001

Source DB:  PubMed          Journal:  J Glob Antimicrob Resist        ISSN: 2213-7165            Impact factor:   4.035


  10 in total

1.  ESBL/pAmpC-Producing Escherichia coli Causing Urinary Tract Infections in Non-Related Companion Animals and Humans.

Authors:  Adriana Belas; Cátia Marques; Juliana Menezes; Luís Telo da Gama; Patrícia Cavaco-Silva; Constança Pomba
Journal:  Antibiotics (Basel)       Date:  2022-04-22

2.  Molecular and microbiological report of a hospital outbreak of NDM-1-carrying Enterobacteriaceae in Mexico.

Authors:  Paola Bocanegra-Ibarias; Elvira Garza-González; Rayo Morfín-Otero; Humberto Barrios; Licet Villarreal-Treviño; Eduardo Rodríguez-Noriega; Ulises Garza-Ramos; Santiago Petersen-Morfin; Jesus Silva-Sanchez
Journal:  PLoS One       Date:  2017-06-21       Impact factor: 3.240

3.  Genetic Platforms of blaCTX-M in Carbapenemase-Producing Strains of K. pneumoniae Isolated in Chile.

Authors:  Sergio Carrasco-Anabalón; Alejandra Vera-Leiva; Mario Quezada-Aguiluz; María F Morales-Rivera; Celia A Lima; Jorge Fernández; Soledad Ulloa; Mariana Domínguez; Gerardo González-Rocha; Helia Bello-Toledo
Journal:  Front Microbiol       Date:  2018-03-06       Impact factor: 5.640

4.  Genomic Epidemiology of an Outbreak of Klebsiella pneumoniae ST471 Producing Extended-Spectrum β-Lactamases in a Neonatal Intensive Care Unit.

Authors:  Yuan Wang; Chunyu Luo; Pengcheng Du; Jinrui Hu; Xiaowei Zhao; Dianjun Mo; Xiaoli Du; Xin Xu; Man Li; Hong Lu; Zhiqiang Zhou; Zhigang Cui; Haijian Zhou
Journal:  Infect Drug Resist       Date:  2020-04-15       Impact factor: 4.003

5.  Transferable Resistance to Highest Priority Critically Important Antibiotics for Human Health in Escherichia coli Strains Obtained From Livestock Feces in Uruguay.

Authors:  Nadia Coppola; Bibiana Freire; Ana Umpiérrez; Nicolás F Cordeiro; Pablo Ávila; Gustavo Trenchi; Gustavo Castro; María Laura Casaux; Martín Fraga; Pablo Zunino; Inés Bado; Rafael Vignoli
Journal:  Front Vet Sci       Date:  2020-11-19

6.  Burden of Fluoroquinolone Resistance in Clinical Isolates of Escherichia coli at the Ho Teaching Hospital, Ghana.

Authors:  John Gameli Deku; Kwabena Obeng Duedu; Emmanuel Ativi; Godsway Edem Kpene; Patrick Kwame Feglo
Journal:  Ethiop J Health Sci       Date:  2022-01

Review 7.  Extended-Spectrum Beta-Lactamases Producing Escherichia coli in South America: A Systematic Review with a One Health Perspective.

Authors:  Carlos Bastidas-Caldes; Daniel Romero-Alvarez; Victor Valdez-Vélez; Roberto D Morales; Andrés Montalvo-Hernández; Cicero Gomes-Dias; Manuel Calvopiña
Journal:  Infect Drug Resist       Date:  2022-09-30       Impact factor: 4.177

8.  Zoonotic Potential and Antibiotic Resistance of Escherichia coli in Neonatal Calves in Uruguay.

Authors:  Ana Umpiérrez; Inés Bado; Martín Oliver; Sofía Acquistapace; Analía Etcheverría; Nora Lía Padola; Rafael Vignoli; Pablo Zunino
Journal:  Microbes Environ       Date:  2017-09-12       Impact factor: 2.912

9.  The prevalence of plasmid-mediated quinolone resistance and ESBL-production in Enterobacteriaceae isolated from urinary tract infections.

Authors:  Robab Azargun; Mohammad Reza Sadeghi; Mohammad Hossein Soroush Barhaghi; Hossein Samadi Kafil; Fatemeh Yeganeh; Mahin Ahangar Oskouee; Reza Ghotaslou
Journal:  Infect Drug Resist       Date:  2018-07-23       Impact factor: 4.003

10.  Prevalence of avian-origin mcr-1-positive Escherichia coli with a potential risk to humans in Tai'an, China.

Authors:  Xiaozhe Li; Lin Li; Lanping Yu; Shuang Liu; Lijuan Liu; Xuting Wei; Yanying Song; Cong Liu; Meijie Jiang; Fangkun Wang
Journal:  Poult Sci       Date:  2020-07-08       Impact factor: 3.352

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.